Home > Compound List > Compound details
174484-41-4 molecular structure
click picture or here to close

N-{3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3,4-dihydro-2H-pyran-5-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide

ChemBase ID: 808
Molecular Formular: C31H33F3N2O5S
Molecular Mass: 602.6643296
Monoisotopic Mass: 602.20622783
SMILES and InChIs

SMILES:
S(=O)(=O)(Nc1cc([C@H](C2=C(O[C@@](CC2=O)(CCc2ccccc2)CCC)O)CC)ccc1)c1ncc(cc1)C(F)(F)F
Canonical SMILES:
CCC[C@@]1(CCc2ccccc2)CC(=O)C(=C(O1)O)[C@@H](c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC
InChI:
InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36,38H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
InChIKey:
NZPXPXAGXYTROM-FYBSXPHGSA-N

Cite this record

CBID:808 http://www.chembase.cn/molecule-808.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
N-{3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3,4-dihydro-2H-pyran-5-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
IUPAC Traditional name
tipranavir
Brand Name
Aptivus (Boehringer Ingelheim)
Aptivus
Synonyms
TPV
tipranavir
Tipranavir
CAS Number
174484-41-4
PubChem SID
46506257
160964271
PubChem CID
65027
54682461

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 5.956316  H Acceptors
H Donor LogD (pH = 5.5) 7.7004013 
LogD (pH = 7.4) 6.8403435  Log P 7.8143587 
Molar Refractivity 163.5574 cm3 Polarizability 59.20148 Å3
Polar Surface Area 105.59 Å2 Rotatable Bonds 11 
Lipinski's Rule of Five false 
Log P 5.71  LOG S -6.46 
Solubility (Water) 2.07e-04 g/l 

PROPERTIES

PROPERTIES

Physical Property Bioassay(PubChem)
Solubility
Insoluble expand Show data source
Hydrophobicity(logP)
6.9 expand Show data source

DETAILS

DETAILS

DrugBank DrugBank
DrugBank - DB00932 external link
Item Information
Drug Groups approved; investigational
Description Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. It is administered with ritonavir in combination therapy to treat HIV infections.
Indication For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Pharmacology Tipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Toxicity Oral LD50 in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
Affected Organisms
Human Immunodeficiency Virus
Biotransformation Hepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.
Absorption Absorption is limited, although no absolute quantification of absorption is available.
Half Life 5-6 hours
Protein Binding Extensive (> 99.9%), to both human serum albumin and α-1-acid glycoprotein.
References
Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005 Oct;68(1):27-35. [Pubmed]
Tipranavir: PNU 140690, tipranivir. Drugs R D. 2006;7(1):55-62. [Pubmed]
Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [Pubmed]
Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005 Oct;68(1):27-35. Pubmed
  • • Tipranavir: PNU 140690, tipranivir. Drugs R D. 2006;7(1):55-62. Pubmed
  • • Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. Pubmed
  • • Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. Pubmed
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle